Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Myelin Density in Normal-Appearing White Matter in Measurements by q-Space Diffusional MRI Correlates with Clinical Disability in Multiple Sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
3-005

We previously developed the qMM method to depict myelin sheaths in vivo and visualize remyelination in demyelinating lesions of MS patients (Fujiyoshi, J Neurosci 2016). A method for evaluating NAWM using the qMM is needed.

To investigate the relationship between myelin density measured by q-space diffusional MRI (q-space myelin map; qMM) in normal-appearing white matter (NAWM) and clinical disability in multiple sclerosis (MS).

Individuals diagnosed with MS according to the 2010 or 2017 McDonald Criteria were recruited at our hospital (April 2016-Sept. 2022). The Expanded Disability Status Scale (EDSS) and MRI including qMM were evaluated in all participants. The Processing Speed Test (PST) (Rao, Mult Scler 2017) was performed when possible. For a quantitative comparison of qMM modalities, we defined Myelin Index (MI) and calculated it between ROIs (selected regions) and a reference (cerebrospinal fluid) with the formula: GVROI/GVREF, where GV indicates median gray value. The MI was assessed in NAWM at the corpus callosum (CC) (average of the CC’s genu and splenium), bilateral cerebral peduncles (CP), bilateral middle cerebellar peduncles (MCP), bilateral posterior limbs of the internal capsule (ICp), and bilateral corona radiata (CR).

Fifty individuals (34 females) with relapsing-remitting MS, n=39, secondary-progressive MS, n=8, and primary-progressive MS, n=3, were examined. Age at evaluation: 42±9.07 years (mean±SD). Disease duration: 10 (7–16.5) years (median (Q1–Q3)). EDSS score: 1.25 (0–3.13). Twenty-six took the PST (score 57 (49.3–72)). The MI of NAWM (average of CC, CP, MCP, ICp and CR) was 5.27±0.31. A negative correlation was observed between the EDSS and the MI of NAWM (r= −0.60, p<0.0001). The PST was positively associated with the MI of the CC (r= 0.55, p=0.003).

The reduction of myelin density in NAWM is associated with deteriorated physical disability and cognitive impairment in MS.

Authors/Disclosures
Haruhiko Motegi, MD (Department of Neurology, Keio University School of Medicine)
PRESENTER
Dr. Motegi has nothing to disclose.
Kenji Kufukihara, MD (Keio University School of Medicine, Department of Neurology) Dr. Kufukihara has nothing to disclose.
Koji Sekiguchi, MD (Keio University School of Medicine) Dr. Sekiguchi has nothing to disclose.
Satoshi Kitagawa, Sr., MD Dr. Kitagawa has nothing to disclose.
Junichi Hata, PhD (Tokyo Metropolitan University) Prof. Hata has nothing to disclose.
Hirokazu Fujiwara, MD (Keio University Hospital) Dr. Fujiwara has nothing to disclose.
Masahiro Jinzaki, MD (Keio University School of Medicine) Prof. Jinzaki has nothing to disclose.
Hideyuki Okano Hideyuki Okano has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for K Pharma Inc. Hideyuki Okano has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SanBio Co Ltd. Hideyuki Okano has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for RMiC. Hideyuki Okano has received stock or an ownership interest from SanBio Co. Ltd. The institution of Hideyuki Okano has received research support from Takeda Pharmaceutical Co. Ltd. The institution of Hideyuki Okano has received research support from Dainippon Sumitomoto Pharmaceutical Co. Ltd. The institution of Hideyuki Okano has received research support from K Pharma Inc.. The institution of Hideyuki Okano has received research support from SanBio Co.Ltd.
Masaya Nakamura, MD,PhD Prof. Nakamura has nothing to disclose.
Jin Nakahara, MD, PhD (Keio University School of Medicine) Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi-Tanabe. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai. Prof. Nakahara has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Prof. Nakahara has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Prof. Nakahara has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Prof. Nakahara has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Chugai. Prof. Nakahara has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Mitsubishi-Tanabe. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Daiichi-Sankyo. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL Behring. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Prof. Nakahara has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Japanese Society for Internal Medicine. The institution of Prof. Nakahara has received research support from EA Pharma. The institution of Prof. Nakahara has received research support from JB. The institution of Prof. Nakahara has received research support from Eisai. The institution of Prof. Nakahara has received research support from Shionogi. The institution of Prof. Nakahara has received research support from Boehringer Ingelheim. The institution of Prof. Nakahara has received research support from Kyowa Kirin. The institution of Prof. Nakahara has received research support from Sumitomo Pharma. The institution of Prof. Nakahara has received research support from Otsuka. The institution of Prof. Nakahara has received research support from Chugai. The institution of Prof. Nakahara has received research support from Teijin. The institution of Prof. Nakahara has received research support from Mitsubishi-Tanabe.